Treating Bax(Δ)2-positive cancer with chemotherapies targeting caspase 8
US9504687B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 2014 |
| Grant date | Nov 29, 2016 |
| Priority date | — |
| Expiry date | Jan 3, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Discovery of a new Bax isoform, BaxΔ2, in cancer cell lines and primary tumors is described. The BaxΔ2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that BaxΔ2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a BaxΔ2 protein (SEQ ID NO. 2).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.